Different doses of coenzyme Q10 in the treatment of dilated cardiomyopathy

AIM To observe the clinical efficacy and safety of different doses of coenzyme Q10 on dilated cardiomyopathy. METHODS 100 patients with dilated cardiomyopathy were randomly divided into two groups, the control group of 40 cases, routine use of diuretics, angiotensin converting enzyme inhibitors, β-blockers and other drugs; the experimental group of 60 cases was randomly divided into 3 groups (20 cases in each subgroup). On the basis of the treatment of the control group, oral coenzyme Q10 10 mg, 30 mg, 50 mg and 3 times/d were added for 3 months. The changes in cardiac function, left ventricular ejection fraction (LVEF), left ventricular end-systolic pressure (LVESD), left ventricular end-diastolic diameter (LVEDD), brain natriuretic peptide (BNP), overall efficiency, re-hospitalization rate and other effects were evaluated. RESULTS The total effective rate was 55% (22/40) in the test group and 80% (48/60) in the control group, the differences were statistically significant (P<0.05). After treatment, the values of LVEF, LVESD, LVEDD and BNP in the test group and the control group after treatment were significantly lower than those before treatment in both groups (P<0.05, 10 mg, 30 mg, 50 mg) Compared with the control group, LVESD value and BNP decreased (P<0.05); LVEF value increased, LVEDD value and BNP decreased in the 30 mg and 50 mg groups when compared with the control group. There were no significant differences between the three dose groups in the test group. The rehospitalization rates of the control group, 10 mg, 30 mg, 50 mg group were 72%, 65%, 40%, 20%; the 10 mg group rehospitalization rate compared with the control group demonstrated no significant difference; the 30 mg and 50 mg rehospitalization rate was significantly lower than the control group, the difference was statistically significant (P<0.05); in the different dose groups, the difference was statistically significant (P<0.05). CONCLUSION Coenzyme Q10 significantly improves cardiac function, prognosis, and rehospitalization rate in patients with dilated cardiomyopathy. High-dose coenzyme Q10 is more effective and reliable in clinical efficacy and safety.